Under the terms of the development and supply agreement, Oxford Biomedica said it intends to manufacture good manufacturing practice (GMP) batches for Boehringer Ingelheim to support the development of viral vectors. The agreement also allows for Oxford Biomedica to manufacture and supply viral vectors in the future, according to the company.

Oxford Biomedica and its subsidiaries have built LentiVector, a lentiviral vector delivery platform that they use to develop in vivo and ex vivo products both internally and with partners.

Boehringer Ingelheim, Cure Genetics to develop novel AAV
Cure Genetics will collaborate with Boehringer Ingelheim to develop novel adeno-associated virus (AAV) vectors leveraging Cure Genetics' proprietary Velp...

Boehringer Ingelheim, Oxford BioTherapeutics partner further on antibodies
Boehringer Ingelheim and Oxford BioTherapeutics are partnering to discover novel targets for cancer immunotherapies using the Oxford Genome Anatomy Project's...

Boehringer Ingelheim acquires Northern Biologics
Boehringer Ingelheim on May 14 announced the acquisition of Northern Biologics, including its preclinical cancer antibody pipeline.

Boehringer Ingelheim expands COVID-19 collaborations
Boehringer Ingelheim announced that it is significantly increasing support for the fight against COVID-19, particularly by adding a number of strategic...